Novartis R&D portfolio update
Posted on06 Nov 2018
Tagsbrolucizumab, canikinumab, cosentyx, crizanlizumab, Entresto, Gilenya, novartis, NSCLC, ofatumumab, R&D portfolio
Comments0
Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline.... Read More